Harmony Biosciences Holdings, Inc. Earnings Recaps
Q2 2026
Aug 6, 2026
Investor optimism was driven by better-than-expected commercial execution, with WAKIX revenue surging 30% year-over-year and a reaffirmed full-year revenue guidance of $1 billion to $1.04 billion. Encouraging early data from the BP-205 orexin-2 agonist pipeline also added confidence.
Key takeaways
- WAKIX net revenue hit a record $261.3 million in Q2, up 30% year-over-year and 21% sequentially after seasonal headwinds in Q1.
- Full-year 2026 net revenue guidance reiterated at $1 billion to $1.04 billion, consistent with previous outlook.
- Promising Phase I single ascending dose data for BP-205 support its potential as a best-in-class orexin-2 receptor agonist with once-daily dosing potential.
- Multiple upcoming data catalysts for BP-205 expected over the next six months, including Phase II trials starting mid-2027.
- Strong balance sheet with approximately $963 million in cash enables continued investment in pipeline and strategic business development opportunities.
Q3 2025
Nov 5, 2025
Harmony Biosciences reported a strong third quarter in 2025, achieving $239.5 million in net revenue—a 29% year-over-year increase—while raising its revenue guidance for the year.
Key takeaways
- Record patient additions for WAKIX, averaging 8,100 patients, a significant increase of 500 patients this quarter.
- Q3 net revenue guidance raised from $820 million to a new range of $845 million to $865 million, driven by strong commercial performance.
- Robust cash generation of $106 million, increasing total cash reserves to $778 million.
- Harmony is poised for future growth with ongoing development of its late-stage pipeline, including multiple upcoming catalyst events.